证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 编号：2022-025 | --- | --- | --- | --- | --- | --- | |---------------|-----------------|----------------------------------------------------|-------|-------|-------| | | | | | | | | 投资者 关系活 | 特定对象调研 | 分析师会议 | | | | | 动类别 | | □媒体采访 □业绩说明会 | | | | | | | □新闻发布会 □路演活动 | | | | | | 现场参观 | | | | | | | 其他 （电话） | | | | | | 参与单 位名称 | | 国元证券：马云涛；华西证券：徐顺利 | | | | | 及人员姓名 | | 鹏扬基金伍智勇、崔洁铭；招商信诺资产：詹孝颖； | | | | | | | 勤远投资：魏雅雯；睿郡资产：魏志华； | | | | | | | 凯昇资本：叶挺；金友创智资产：李宁；杭银理财：王哲 | | ...

Revenue and Profit Growth - Revenue for Q3 2022 reached ¥175,075,260.37, an increase of 116.03% compared to the same period last year[6] - Net profit attributable to shareholders was ¥60,200,473.64, reflecting a growth of 155.42% year-over-year[6] - The net profit excluding non-recurring items was ¥59,114,873.33, up 153.75% from the previous year[6] - Basic earnings per share for the quarter was ¥0.56, a 93.10% increase compared to the same period last year[6] - The company's operating revenue increased to ¥222,306,353.54, representing a growth of 89.26% compared to the same period last year, driven by a strengthened business model of "technology transformation + entrusted development + profit sharing"[14] - Total operating revenue for the third quarter of 2022 reached ¥420,743,410.29, a significant increase of 89.5% compared to ¥222,306,353.54 in the same period last year[31] - The company reported a total profit of 154,492,098.56 CNY for the quarter, compared to 70,413,983.03 CNY in the previous year, indicating an increase of about 119.8%[37] Assets and Liabilities - Total assets as of September 30, 2022, were ¥2,722,802,500.36, a decrease of 6.91% from the end of the previous year[6] - The total liabilities decreased to ¥305,608,047.34 from ¥607,099,838.11, a reduction of 49.7%[27] - Estimated liabilities rose by 46.38% to ¥125,635,824.68, as the company recognized liabilities corresponding to the progress of entrusted and self-developed projects[14] - The equity attributable to shareholders of the parent company increased to ¥2,417,361,324.83 from ¥2,317,911,097.31, an increase of 4.3%[30] Cash Flow and Investments - Cash flow from operating activities for the year-to-date was ¥157,648,719.74, an increase of 154.33% year-over-year[6] - The net cash flow from operating activities reached ¥157,648,719.74, a significant increase of 154.33% year-on-year, attributed to higher operating income and improved accounts receivable collection[17] - The company experienced a 240.22% increase in cash flow from investing activities, resulting in a net outflow of ¥467,493,195.28, driven by ongoing project investments[17] - Cash outflows from investing activities amounted to 471,497,885.54 CNY, compared to 228,684,414.89 CNY in the previous year, leading to a net cash flow from investing activities of -467,493,195.28 CNY[40] Expenses and Financial Performance - Research and development expenses surged by 167.37% to ¥42,489,710.84, reflecting the company's ongoing investment in innovative and generic drug development[14] - The company's income tax expense increased by 56.02% to ¥9,328,893.49, reflecting higher profits during the reporting period[17] - The financial expenses increased dramatically by 2912.60%, amounting to ¥1,177,436.68, primarily due to increased interest on raised funds[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,547, indicating a stable shareholder base[18] Inventory and Contract Assets - Inventory increased by 142.23% to ¥55,353,854.97 due to increased production activities[11] - Contract assets grew by 109.58% to ¥98,910,980.94, driven by rapid revenue growth[11] - The company reported a significant increase in prepayments, which rose by 100.91% to ¥26,603,377.79, attributed to increased clinical business activities[11] Cash and Cash Equivalents - The company reported cash outflows from financing activities amounted to 361,282,406.46 CNY, while cash inflows were recorded at 126,747,271.43 CNY, resulting in a net cash flow from financing activities of -361,282,406.46 CNY[40] - The ending cash and cash equivalents balance was 1,337,874,628.84 CNY, down from 157,569,933.40 CNY at the end of the previous year[40] - The company's cash and cash equivalents decreased to ¥1,341,573,128.84 from ¥2,013,001,510.85, a decline of 33.3%[24]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[2] - The net profit attributable to shareholders was RMB 100 million, with a growth rate of 15% compared to the same period last year[2] - Future guidance indicates expected revenue growth of 25% for the full year 2022, projecting total revenue of RMB 1.2 billion[2] - The company's revenue for the reporting period reached CNY 245,668,149.92, representing a 73.91% increase compared to CNY 141,262,964.39 in the same period last year[36] - Net profit attributable to shareholders was CNY 85,021,258.82, an increase of 107.62% from CNY 40,949,487.61 year-on-year[36] - The net cash flow from operating activities was CNY 105,093,103.55, a significant increase of 295.01% compared to CNY 26,604,864.69 last year[36] - Basic earnings per share increased to CNY 0.79, reflecting a growth of 58.00% from CNY 0.50 in the previous year[36] - The company reported a significant increase in financial expenses, with a change of -4,636.10% to -¥22,452,303.28, mainly due to increased interest on raised funds[113] - The company experienced a 44.74% increase in income tax expenses to ¥4,734,668.68, correlating with the rise in profit[113] Market Expansion and Product Development - User data showed an increase in active users by 30%, reaching a total of 1 million active users by the end of June 2022[2] - The company plans to launch two new products in Q4 2022, aiming to capture a 10% market share in the new segments[2] - The company is expanding its market presence in Southeast Asia, targeting a 15% increase in sales from this region by the end of 2023[2] - The company continues to focus on the development of new drugs and technologies, enhancing its market position and expanding its product offerings[33] - The company is exploring acquisition opportunities to enhance its product portfolio and market reach, with a focus on strategic partnerships[2] - The company is focusing on market expansion strategies to enhance its competitive position in the industry[176] Research and Development - Research and development expenses increased by 40%, totaling RMB 50 million, to support new product development and innovation[2] - The company has retained sales rights sharing agreements with some clients, allowing for continuous revenue generation from drug sales throughout the product lifecycle[56] - The company is currently developing 6 innovative drug projects targeting various pathways, with one project (BIOS-0618) having received clinical approval and entering Phase I trials[59] - The company has established a complete CDMO service platform to enhance drug development efficiency and reduce costs, facilitating the transition from laboratory research to commercial production[57] - The company has over 250 ongoing independent R&D projects with high customer acceptance, which is expected to drive future revenue growth[99] - The company is focusing on six innovative drug projects, all classified as Category 1 new drugs, targeting areas such as neuropathic pain, tumors, and non-alcoholic fatty liver disease, indicating a broad market potential[99] - The company has a strong R&D team with 874 technical R&D personnel, accounting for 73.76% of total employees, and 80.05% of these personnel hold a bachelor's degree or higher[109] - The company is actively investing in R&D, with discussions on the planning and investment in the Semaglutide project and the conversion of R&D achievements into commercial results[166] Risk Management - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[5] - The company faces risks related to drug development failures and long development cycles, which may impact future business performance[151][155] - The company plans to enhance its R&D team and optimize drug development processes to mitigate risks associated with drug development failures[154] - The company is closely monitoring regulatory policies in the pharmaceutical industry to ensure compliance and mitigate risks[159] Environmental Management - The company has implemented various measures to control pollution, including optimizing production processes to reduce waste gas emissions and enhance solvent recovery efficiency[196] - The company has established a comprehensive wastewater treatment system, ensuring that wastewater meets discharge standards through various pre-treatment methods[197] - The company’s environmental management includes regular monitoring and compliance with national pollution discharge standards[193] - The company has adopted a closed production system to minimize unorganized waste gas emissions during manufacturing processes[196] - The company has established a solid waste management ledger and improved the hazardous waste management system within the plant[200] Employee Management and Incentives - The company has implemented stock incentive plans for 197 executives and core employees in June 2022, resulting in significant share-based payment expenses[160] - The company plans to implement an equity incentive plan aimed at enhancing employee motivation and aligning interests with shareholders[175] - The company has a total of 1,130,653 shares allocated to senior management and core employees through a strategic placement plan[187] - The company is focusing on optimizing its human resource management system to enhance employee value and overall profitability[162] Financial Strategy and Investments - The company has a total of CNY 36,387 million in excess raised funds, which will be used to permanently supplement working capital[136] - The company has invested CNY 100,452,602.68 in the Jinxi Industrialization Project Phase II, with a cumulative investment of CNY 112,243,862.49[127] - The company utilized CNY 16,558.14 million of the raised funds during the reporting period, with a cumulative investment of the same amount[131] - The company has not reported any significant changes in the measurement attributes of its main assets during the reporting period[126]

Revenue and Profit - Revenue for Q1 2022 reached ¥95,802,322.64, an increase of 114.26% compared to ¥44,712,533.27 in the same period last year[4] - Net profit attributable to shareholders was ¥19,529,827.85, up 352.57% from ¥4,315,275.49 year-on-year[4] - Basic earnings per share increased to ¥0.18, representing a growth of 260.00% compared to ¥0.05 in the previous year[4] - Operating profit for the quarter was ¥16,859,281.24, up from ¥3,433,329.27, reflecting a growth of approximately 390% year-over-year[33] - Net profit attributable to the parent company was ¥19,529,827.85, compared to ¥4,315,275.49 in the previous year, marking an increase of about 353%[33] - Basic and diluted earnings per share for the quarter were both ¥0.18, compared to ¥0.05 in the same period last year, representing a 260% increase[36] Expenses and Costs - Research and development expenses surged to ¥44,014,040.32, a 263.32% increase from ¥12,114,330.77 in the same period last year[12] - The total operating costs for the quarter were ¥80,721,016.07, up from ¥41,034,563.58, which is an increase of about 97% year-over-year[30] - The company reported a financial expense of -¥11,046,988.42, a significant improvement compared to ¥260,929.15 in the previous year[30] Cash Flow and Liquidity - The net cash flow from operating activities was -¥33,055,022.37, a decline of 545.00% compared to -¥5,124,775.28 in the previous year[12] - Operating cash inflow for the period was CNY 104,198,451.75, compared to CNY 47,901,106.52 in the previous period, indicating a significant increase[37] - Cash outflow from operating activities totaled CNY 137,253,474.12, up from CNY 53,025,881.80 in the previous period, resulting in a net cash flow from operating activities of CNY -33,055,022.37[37] - Cash outflow for investing activities was CNY 107,504,546.11, compared to CNY 89,178,749.68 in the previous period, leading to a net cash flow from investing activities of CNY -107,499,855.85[40] - Cash outflow from financing activities reached CNY 240,411,585.24, significantly higher than CNY 1,935,857.07 in the previous period, resulting in a net cash flow from financing activities of CNY -240,411,585.24[40] - The net increase in cash and cash equivalents was CNY -380,966,463.46, compared to CNY -74,547,033.01 in the previous period[40] - The ending balance of cash and cash equivalents was CNY -322,908,967.51, down from CNY 58,057,495.95 at the beginning of the period[40] Assets and Liabilities - Total assets decreased by 10.53% to ¥2,616,781,425.54 from ¥2,924,873,724.42 at the end of the previous year[4] - The total liabilities include short-term borrowings of ¥5,006,111.11 and accounts payable of ¥47,852,813.03, with accounts payable decreasing from ¥129,832,845.11[23] - Total liabilities decreased to ¥278,624,958.90 from ¥607,099,838.11, a reduction of about 54%[26] - The company's total equity increased to ¥2,338,156,466.64 from ¥2,317,773,886.31, reflecting a growth of approximately 0.9%[26] - The company reported a total of 1,888,798,999.70 in current assets, down from 2,225,554,608.43, a decrease of approximately 15%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,500, with no preferred shareholders having restored voting rights[13] - The largest shareholder, Shao Chunnan, holds 18.72% of the shares, amounting to 20,250,000 shares[16] - The company has no preferred shareholders and no changes in restricted shares during the reporting period[20] Other Financial Information - The company received government subsidies amounting to ¥6,015,474.42 during the reporting period[7] - The company reported a significant increase in accounts receivable, which rose by 141.23% to ¥1,100,000.00 from ¥456,000.00 at the beginning of the period[8] - Accounts receivable increased to ¥99,707,532.34 from ¥76,755,728.68, reflecting a growth of about 30%[20] - Inventory at the end of the reporting period is ¥31,018,704.39, up from ¥22,851,850.91, indicating an increase of approximately 36%[23] - The company received CNY 15,809,390.72 in tax refunds during the period, which was not reported in the previous period[37] - The company paid CNY 49,847,041.33 to employees, an increase from CNY 27,929,025.81 in the previous period[37] Audit and Reporting - The first quarter report was not audited, indicating a need for caution in interpreting the financial results[41]

Financial Performance - The company's operating revenue for 2021 was CNY 374,311,815.33, representing an increase of 80.61% compared to CNY 207,247,808.83 in 2020[32]. - The net profit attributable to shareholders of the listed company in 2021 was CNY 111,088,253.50, a growth of 93.52% from CNY 57,403,684.97 in 2020[32]. - The net profit after deducting non-recurring gains and losses was CNY 102,894,486.94, up 87.54% from CNY 54,865,744.32 in 2020[32]. - The net cash flow from operating activities reached CNY 145,424,030.12, an increase of 167.52% compared to CNY 54,360,128.09 in 2020[32]. - The total assets at the end of 2021 amounted to CNY 2,924,873,724.42, a significant increase of 357.16% from CNY 639,794,047.15 at the end of 2020[32]. - The net assets attributable to shareholders of the listed company were CNY 2,317,911,097.31, reflecting a growth of 581.36% from CNY 340,186,622.89 in 2020[32]. - The basic earnings per share for 2021 was CNY 1.37, representing a 92.96% increase from CNY 0.71 in 2020[32]. - The weighted average return on net assets increased to 27.94% in 2021 from 18.80% in 2020[32]. - The company reported a net profit of CNY 46,569,470.14 in the fourth quarter of 2021, showing strong quarterly performance[35]. - The company achieved a revenue share of 32.17 million yuan (excluding tax) from the jointly invested project with Huayuan Pharmaceutical for Valsartan and Amlodipine tablets in 2021[97]. - The company reported a significant increase in sales expenses, which rose by 244.59% to CNY 6.71 million, indicating increased marketing efforts[132]. - The company achieved a subtotal of ¥53,128,997.90 in preclinical pharmaceutical research, which is a 49.63% increase from the previous year[156]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 6.00 RMB (including tax) for every 10 shares, totaling 108,166,667 shares[8]. Risks and Compliance - The report highlights potential risks in the company's future development strategies, urging investors to be cautious[8]. - The company emphasizes the importance of accurate and complete financial reporting, ensuring accountability from its management team[6]. - The company has no significant discrepancies between financial reports prepared under international accounting standards and Chinese accounting standards[36]. Research and Development - The company has established a comprehensive drug development and quality assurance system, enhancing its competitive advantage in the market[57]. - The company is currently developing five innovative drug projects targeting various pathways, with BIOS-0618 having received clinical approval and entering Phase I trials[73]. - The company has established strategic partnerships with multiple clinical trial bases, enhancing its clinical trial service capabilities[60]. - The company has established core technology platforms for innovative drug research, generic drug consistency evaluation, and pharmacokinetics studies, supporting its rapid and sustainable development[88]. - The company has developed a platform for inhalation formulations since 2014, ensuring the quality of inhalation generic drugs is comparable to reference formulations[90]. - The company has accumulated rich technical experience in the development of controlled-release formulations since 2017, focusing on various key processes for industrialization[90]. - The company has successfully developed a variety of inhalation formulations, leveraging its complete research and development system[90]. - The company has focused on developing new indications for drugs based on unmet medical needs and unique drug properties[90]. - The company has established a strong foundation in pharmacological research since its inception, aligning with national requirements for generic drug quality and efficacy[90]. - The company has completed over 200 compatibility studies, with more than 30 results passing CDE technical review and on-site verification, aiding clients in obtaining production licenses[96]. - The company has developed multiple advanced drug delivery technologies, including multi-layer skeleton sustained-release technology and transdermal drug delivery systems[95]. - The company has accumulated rich technical experience in taste masking technology, successfully applying coating technology for taste improvement since 2019[96]. - The company has established a BE/PK research platform with over 100 BE/PK project experiences, addressing issues in study design, biological sample analysis, and data deviation[96]. - The company has a total of 33 R&D projects with sales rights sharing as of the end of the reporting period[97]. - The company has made significant progress in its R&D projects, including the development of new drugs targeting neuropathic pain and tumors, with IND clinical approval obtained for BIOS-0618[157]. Market and Industry Trends - The CRO market is projected to grow from $57.9 billion in 2018 to $95.2 billion by 2023, with a compound annual growth rate (CAGR) of 10.3%[45]. - The Chinese CDMO market is expected to reach ¥123.5 billion by 2025, with a CAGR of 31.26% from 2020 to 2025[56]. - The global CDMO market is forecasted to grow from $35.3 billion in 2020 to $106.6 billion by 2025, with a CAGR of 13.94%[54]. - The CRO market in China has seen a CAGR of 29.2% from 2014 to 2018, indicating rapid growth compared to the global average[48]. - The CRO industry in China has significant growth potential, with an estimated market space of approximately CNY 34 billion driven by the development of generic drugs and consistency evaluations[192]. - The global pharmaceutical CDMO market grew from $35.3 billion in 2016 to $55.5 billion in 2020, with a CAGR of 11.98%[197]. - The Chinese pharmaceutical CDMO market expanded from ¥10.5 billion in 2016 to ¥31.7 billion in 2020, achieving a CAGR of 31.82%[198]. - The global chemical CDMO market increased from $25.9 billion in 2016 to $37.5 billion in 2020, with a CAGR of 9.69%[197]. - The Chinese chemical CDMO market grew from ¥8 billion in 2016 to ¥22.6 billion in 2020, with a CAGR of 29.64%[198]. Workforce and Human Resources - The company has a workforce of 765 employees and operates in a 18,000 m² facility, equipped with advanced instruments and equipment[57]. - The proportion of employees with a bachelor's degree or higher is 67.71%, with 71.89% of the workforce engaged in technical R&D[130]. - The number of R&D personnel increased by 47.06% from 374 in 2020 to 550 in 2021, with a notable shift in educational background[160]. - The proportion of R&D personnel with a bachelor's degree increased by 30.92% from 194 in 2020 to 255 in 2021[160]. Compliance and Quality Assurance - The company has developed a comprehensive compliance training program for all employees, ensuring they are qualified before starting operations[118]. - The quality assurance (QA) department conducts regular on-site inspections to monitor compliance and address any identified issues[118]. - The company has a dedicated warehouse management team to oversee material management, ensuring proper tracking and compliance[118]. - Stability testing samples are managed by the QA department, with online monitoring systems in place to ensure sample conditions meet testing requirements[118]. - The company has established a continuous and unmodifiable ledger for recording the usage of research and development equipment and materials[118]. - The company has established a comprehensive quality management system to ensure the authenticity and reliability of experimental data[115]. Strategic Initiatives - The company has established strategic partnerships with cooperative hospitals to conduct PK/BE studies[96]. - The company has implemented a strategy to retain partial rights for certain products recommended to clients, allowing for ongoing revenue sharing post-market launch[109]. - The company is focusing on five first-class innovative drug projects, enhancing its R&D pipeline in the field of generic drugs while increasing investment in innovative drugs[165]. - The company aims to develop high-quality and high-end generic drugs, leveraging CRO capabilities to shorten development cycles and improve efficiency[194]. - The company plans to expand its business scope to include pharmaceuticals, medical devices, health products, and chemicals, positioning itself as a comprehensive health product R&D enterprise[198]. Financial Management - The company raised a total of CNY 215,251.67 million from its initial public offering, with a net amount of CNY 186,343.01 million after deducting issuance costs[177]. - As of December 31, 2021, the company had not utilized any of the raised funds, which are stored in a dedicated account[177]. - The company has a total of CNY 121,291.23 million in unused raised funds, which will be allocated based on future development needs[181]. - The estimated liabilities increased to CNY 85,827,359.01, reflecting a 2.93% rise, attributed to the expansion of business scale and increased operating revenue[173]. - The company reported a total of non-current liabilities due within one year amounting to CNY 229,120,819.76, representing a 7.83% increase[173]. - The cash flow from investment activities showed a net outflow of ¥251,158,415.14 in 2021, a slight improvement of 1.81% compared to the previous year[166]. - The net cash flow from financing activities surged by 1,264.99% to ¥1,982,131,366.91 in 2021, largely due to the proceeds from the public offering of shares[167].